U.S. Fabry Patients Petition for Same Fabrazyme Preference as EU

International Pharmaceutical Regulatory Monitor
A A
A group of U.S. patients with Fabry disease intensified their campaign to get an open license for Genzyme’s Fabrazyme during an ongoing shortage, citing preferential treatment of Fabry patients in Europe.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00